BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 38359819)

  • 1. Pan-cancer proteogenomics characterization of tumor immunity.
    Petralia F; Ma W; Yaron TM; Caruso FP; Tignor N; Wang JM; Charytonowicz D; Johnson JL; Huntsman EM; Marino GB; Calinawan A; Evangelista JE; Selvan ME; Chowdhury S; Rykunov D; Krek A; Song X; Turhan B; Christianson KE; Lewis DA; Deng EZ; Clarke DJB; Whiteaker JR; Kennedy JJ; Zhao L; Segura RL; Batra H; Raso MG; Parra ER; Soundararajan R; Tang X; Li Y; Yi X; Satpathy S; Wang Y; Wiznerowicz M; González-Robles TJ; Iavarone A; Gosline SJC; Reva B; Robles AI; Nesvizhskii AI; Mani DR; Gillette MA; Klein RJ; Cieslik M; Zhang B; Paulovich AG; Sebra R; Gümüş ZH; Hostetter G; Fenyö D; Omenn GS; Cantley LC; Ma'ayan A; Lazar AJ; Ceccarelli M; Wang P;
    Cell; 2024 Feb; 187(5):1255-1277.e27. PubMed ID: 38359819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteogenomic data and resources for pan-cancer analysis.
    Li Y; Dou Y; Da Veiga Leprevost F; Geffen Y; Calinawan AP; Aguet F; Akiyama Y; Anand S; Birger C; Cao S; Chaudhary R; Chilappagari P; Cieslik M; Colaprico A; Zhou DC; Day C; Domagalski MJ; Esai Selvan M; Fenyö D; Foltz SM; Francis A; Gonzalez-Robles T; Gümüş ZH; Heiman D; Holck M; Hong R; Hu Y; Jaehnig EJ; Ji J; Jiang W; Katsnelson L; Ketchum KA; Klein RJ; Lei JT; Liang WW; Liao Y; Lindgren CM; Ma W; Ma L; MacCoss MJ; Martins Rodrigues F; McKerrow W; Nguyen N; Oldroyd R; Pilozzi A; Pugliese P; Reva B; Rudnick P; Ruggles KV; Rykunov D; Savage SR; Schnaubelt M; Schraink T; Shi Z; Singhal D; Song X; Storrs E; Terekhanova NV; Thangudu RR; Thiagarajan M; Wang LB; Wang JM; Wang Y; Wen B; Wu Y; Wyczalkowski MA; Xin Y; Yao L; Yi X; Zhang H; Zhang Q; Zuhl M; Getz G; Ding L; Nesvizhskii AI; Wang P; Robles AI; Zhang B; Payne SH;
    Cancer Cell; 2023 Aug; 41(8):1397-1406. PubMed ID: 37582339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proteogenomics data-driven knowledge base of human cancer.
    Liao Y; Savage SR; Dou Y; Shi Z; Yi X; Jiang W; Lei JT; Zhang B
    Cell Syst; 2023 Sep; 14(9):777-787.e5. PubMed ID: 37619559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
    Groeneveld CS; Sanchez-Quiles V; Dufour F; Shi M; Dingli F; Nicolle R; Chapeaublanc E; Poullet P; Jeffery D; Krucker C; Maillé P; Vacherot F; Vordos D; Benhamou S; Lebret T; Micheau O; Zinovyev A; Loew D; Allory Y; de Reyniès A; Bernard-Pierrot I; Radvanyi F
    Eur Urol; 2024 May; 85(5):483-494. PubMed ID: 37380559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.
    Zhang Y; Chen F; Chandrashekar DS; Varambally S; Creighton CJ
    Nat Commun; 2022 May; 13(1):2669. PubMed ID: 35562349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteogenomic interrogation of cancer cell lines: an overview of the field.
    Tsang O; Wong JWH
    Expert Rev Proteomics; 2021 Mar; 18(3):221-232. PubMed ID: 33877947
    [No Abstract]   [Full Text] [Related]  

  • 7. Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
    Joshi SK; Piehowski P; Liu T; Gosline SJC; McDermott JE; Druker BJ; Traer E; Tyner JW; Agarwal A; Tognon CE; Rodland KD
    Annu Rev Pharmacol Toxicol; 2024 Jan; 64():455-479. PubMed ID: 37738504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
    Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
    J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy.
    Krug K; Jaehnig EJ; Satpathy S; Blumenberg L; Karpova A; Anurag M; Miles G; Mertins P; Geffen Y; Tang LC; Heiman DI; Cao S; Maruvka YE; Lei JT; Huang C; Kothadia RB; Colaprico A; Birger C; Wang J; Dou Y; Wen B; Shi Z; Liao Y; Wiznerowicz M; Wyczalkowski MA; Chen XS; Kennedy JJ; Paulovich AG; Thiagarajan M; Kinsinger CR; Hiltke T; Boja ES; Mesri M; Robles AI; Rodriguez H; Westbrook TF; Ding L; Getz G; Clauser KR; Fenyö D; Ruggles KV; Zhang B; Mani DR; Carr SA; Ellis MJ; Gillette MA;
    Cell; 2020 Nov; 183(5):1436-1456.e31. PubMed ID: 33212010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms.
    Lehtiö J; Arslan T; Siavelis I; Pan Y; Socciarelli F; Berkovska O; Umer HM; Mermelekas G; Pirmoradian M; Jönsson M; Brunnström H; Brustugun OT; Purohit KP; Cunningham R; Foroughi Asl H; Isaksson S; Arbajian E; Aine M; Karlsson A; Kotevska M; Gram Hansen C; Drageset Haakensen V; Helland Å; Tamborero D; Johansson HJ; Branca RM; Planck M; Staaf J; Orre LM
    Nat Cancer; 2021 Nov; 2(11):1224-1242. PubMed ID: 34870237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.
    Ji S; Feng L; Fu Z; Wu G; Wu Y; Lin Y; Lu D; Song Y; Cui P; Yang Z; Sang C; Song G; Cai S; Li Y; Lin H; Zhang S; Wang X; Qiu S; Zhang X; Hua G; Li J; Zhou J; Dai Z; Wang X; Ding L; Wang P; Gao D; Zhang B; Rodriguez H; Fan J; Clevers H; Zhou H; Sun Y; Gao Q
    Sci Transl Med; 2023 Jul; 15(706):eadg3358. PubMed ID: 37494474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Precision oncology from a proteogenomics perspective].
    Huang Y; Wu S; Shu K; Zhu Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3616-3627. PubMed ID: 36305397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities.
    Vasaikar S; Huang C; Wang X; Petyuk VA; Savage SR; Wen B; Dou Y; Zhang Y; Shi Z; Arshad OA; Gritsenko MA; Zimmerman LJ; McDermott JE; Clauss TR; Moore RJ; Zhao R; Monroe ME; Wang YT; Chambers MC; Slebos RJC; Lau KS; Mo Q; Ding L; Ellis M; Thiagarajan M; Kinsinger CR; Rodriguez H; Smith RD; Rodland KD; Liebler DC; Liu T; Zhang B;
    Cell; 2019 May; 177(4):1035-1049.e19. PubMed ID: 31031003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.
    Gillette MA; Satpathy S; Cao S; Dhanasekaran SM; Vasaikar SV; Krug K; Petralia F; Li Y; Liang WW; Reva B; Krek A; Ji J; Song X; Liu W; Hong R; Yao L; Blumenberg L; Savage SR; Wendl MC; Wen B; Li K; Tang LC; MacMullan MA; Avanessian SC; Kane MH; Newton CJ; Cornwell M; Kothadia RB; Ma W; Yoo S; Mannan R; Vats P; Kumar-Sinha C; Kawaler EA; Omelchenko T; Colaprico A; Geffen Y; Maruvka YE; da Veiga Leprevost F; Wiznerowicz M; Gümüş ZH; Veluswamy RR; Hostetter G; Heiman DI; Wyczalkowski MA; Hiltke T; Mesri M; Kinsinger CR; Boja ES; Omenn GS; Chinnaiyan AM; Rodriguez H; Li QK; Jewell SD; Thiagarajan M; Getz G; Zhang B; Fenyö D; Ruggles KV; Cieslik MP; Robles AI; Clauser KR; Govindan R; Wang P; Nesvizhskii AI; Ding L; Mani DR; Carr SA;
    Cell; 2020 Jul; 182(1):200-225.e35. PubMed ID: 32649874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms.
    Wang Y; Luo R; Zhang X; Xiang H; Yang B; Feng J; Deng M; Ran P; Sujie A; Zhang F; Zhu J; Tan S; Xie T; Chen P; Yu Z; Li Y; Jiang D; Zhang X; Zhao JY; Hou Y; Ding C
    Nat Commun; 2023 Jan; 14(1):505. PubMed ID: 36720864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
    Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer proteogenomics: current impact and future prospects.
    Mani DR; Krug K; Zhang B; Satpathy S; Clauser KR; Ding L; Ellis M; Gillette MA; Carr SA
    Nat Rev Cancer; 2022 May; 22(5):298-313. PubMed ID: 35236940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
    Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
    Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decomprolute is a benchmarking platform designed for multiomics-based tumor deconvolution.
    Feng S; Calinawan A; Pugliese P; Wang P; Ceccarelli M; Petralia F; Gosline SJC
    Cell Rep Methods; 2024 Feb; 4(2):100708. PubMed ID: 38412834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplified and Unified Access to Cancer Proteogenomic Data.
    Lindgren CM; Adams DW; Kimball B; Boekweg H; Tayler S; Pugh SL; Payne SH
    J Proteome Res; 2021 Apr; 20(4):1902-1910. PubMed ID: 33560848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.